Design, Development and Evaluation of Gastro- Retentive Mucoadhesive Microballons of Lansoprazole for Management of Peptic Ulcer

Authors

  • Jitendra Kumar School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P
  • Dharmendra Singh Rajput School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P
  • Naveen Gupta School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P
  • Neeraj K Sharma School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

DOI:

https://doi.org/10.22270/ajprd.v10i6.1092

Keywords:

Lasnoprazole, Preformulation, In vitro, Peptic ulcer, Microballona

Abstract

A major problem for gastric delivery is the attainment of an optimal concentration at site of action with maximum bioavailability of drugs. The problem is associated with the conventional dosage form for peptic ulcer diseases is frequent dosing due to the low half life. The bioavailability of an instilled compound is generally low from 1.5 – 3.0 h and low solubility, with only a small fraction reaching the target site. In the present study an attempt was made to develop a mucoadhesive Microballons of  Lansoprazole with variation in polysaccharide polymeric combination with different ratios to increase mucoadhesion at gastric mucosa, which increase the gastric residence time, thus increase the bioavailability.The result indicated that the drug have maximum solubility water, and also  soluble in 0.1 N HCl. The partition coefficient of  Lansoprazole HCl was found to be (0.2442). The FTIR spectrum is shown in Figure. The characteristic peaks of  Lansoprazole HCl were observed at 3290, 3220, 3127, 3084, 2975, 2820, 2819, 2781, 1621, 1517, 1420, 1418, 1425, 1412, 1317 and 1319 cm-1.The prepared mucoadhesive microballons were determine for percentage yield and the range of percentage yield is 89.2 % - 95.9. The Shape and surface morphology of prepared mucoadhesive microballons was shown by photograph by scanning electron microscope in Figure.

 

Downloads

Download data is not yet available.

Author Biographies

Jitendra Kumar, School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

Dharmendra Singh Rajput, School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

Naveen Gupta, School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

Neeraj K Sharma, School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

School of Pharmacy, Madhyanchal Professional University, Bhopal, M.P

References

1. Geboes K, Dekker W, Mulder CJ, Nusteling K. Dutch study group: long-term lansoprazole treatment for gastro-esophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther. 2001; 15:1819–1826. doi:10.1046/j.1365-2036.2001.01105.x. [PubMed]
2. Poynard T, Staub JL, Lemerez M, Deltenre M, Rekacevicz C, Sallerin V. Efficacy and safety of lansoprazole 15 mg OAD or 30 mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial. Gastroenterology. 1995; 108(Suppl):A195. doi:10.1016/0016-5085(95)23441-1. Abstract.
3. Selin JH, Pasrija PJ. Pharmacotherapy of Inflammatory Bowel Disease. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 11th edition. New York: McGraw Hill companies, Inc., USA; 2006. P. 1010.
4. Ding X, Alani AW, Robinson JR. Extended-Release and Targeted Drug Delivery Systems. In: Bringer P, Gupta PK, Felton KL, editors. Remington: The Science And Practice of Pharmacy. 21st edition. Baltimore: Lippincott Williams & Wilkins, USA; 2005. P. 939. (Vol 1).
5. Ansel HC. Pharmaceutical Dosage Forms and Drug Delivery Systems. 5th edition. London: Lea & Febiger, Philadelphia, UK; 1990. P. 69. Basel; 2002. P. 501.
6. Shivakumar HG, Vishakante D, Kumar TMP. Floating Controlled Drug Delivery Systems for Prolong Gastric Residence. Indian J Pharm Educ. 2004; 38(4):172-179.
7. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. Int J Pharm.1996; 136:117-139.
8. Park K. Enzyme-digestible swelling as platforms for long term oral drug delivery: synthesis and characterization. Biomaterials. 1988; 9:435.
9. Fujimori J, Machida Y, Nagai T. Preparation of a magnetically – responsive tablet and configuration of its gastric residence in beagle dogs. STP Pharma Sci. 1994; 4: 425-430.
10. Yie W, Chein. Novel Drug Delivery System 2nd ed. Marcel dekker Inc. New York. 1992; 1-3.
11. Shweta Arora, Floating Drug Delivery Systems. A Review, AAPS Pharm Sci Tech. 2005; 6(3):Article 47, E.372-390.
12. Gangadharappa HV, Pramod Kumar TM, and Shiva Kumar HG. Gastric floating drug delivery systems. Indian J Pharm Educ Res. Oct-Dec 2007; 41 (4): 295-306.
13. Jimenez-Castellanos NR, Zia H, Rhodes CT. Mucoadhesive Drug Delivery Systems. Drug Development and Industrial pharmacy. 1993; 19:143.
14. Baumgartners S, Kristal J, Vrecer F, Vodopivec P, Zorco B. Optimisation of floating matrix tablets and evaluation of their gastric residence time, Int. J. pharm. 2000; 195:125-135.
15. Despande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm. 1996; 22:531-539.
16. Bolton S, Desai S. Floating sustained release therapeutic compositions. US Patent. 4, 814, 179, March 21, 1989.
17. Talukder R, Fassihi R. Gastroretentive delivery systems: Drug Dev and Ind Pharm. 2004; 30(10):1019-1028.
18. Garg Sanjay, Sharma Shringi. Gastroretentive drug delivery systems. Pharmtech. 2003;160-166.
19. Jain NK. Progress in Controlled and Novel Drug Delivery Systems. Edn. 1, CBS Publishers and Distributors, New Delhi, Bangalore. 2004; 84-85.
20. Sangekar S, Ladino WA, Chaudry I, Parr A, Beihn R, Digenis G. Evaluation of the effect of food and specific gravity of tablets on gastric retention time. Int. J. Pharm.1987; 35(3):34-53.
21. Arora Shweta, Ali Javed, Ahuja Alka, Khar RK, Baboota S. Floating drug delivery systems: A review. AAPS Pharm SciTech. 2005; 06(03):E372-E390.
22. Gaba Punam, Gaba Monica, Garg Rajeev, Gupta GD. Available http://www.pharmainfo net / reviews / floating-microballons review. 2008.
23. Hilton AK, Deasy PB. In vitro and invivo evaluation of an oral sustained release floating dosage form of Amoxycillin trihydrate. Int.J.Pham.1992; 86:79-88.
24. Seth PR, Tossounian J. The hydrodynamically balanced systems (HBS), a novel drug delivery system for oral use. Drug Dev Ind Pharm.1984; 10:313-339.
25. Harrigan RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent October 25, 1977; 405:5178.
26. Whiteland L, Fell JT, Collett JH. Development of gastroretentive dosage form. Eur J Pharm Sci, 1996;4 (Suppl.): S182.
27. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microballons for use as floating controlled drug delivery system in stomach. J Pharm Sci. 1992; 81(2):135- 140.
28. Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract, In Domb AJ (Ed.) Polymeric site specific pharmacotherapy. Wiley, Chichester. 1994; 282-283.
29. Mojaverian P, Vlasses PH, Kellner PE, Rocci ML. Effects of gender, posture and age on gastric residence time of an indigestible solid: Pharmaceutical considerations. Pharm Res. 1988; 10:639-664.
30. Vyas SP, Khar RK. Targeted and controlled Drug Delivery Novel carrier system, 1st ed., CBS Publishers and distributors, New Delhi, 2002; 196-217.
31. Singh, B.N., Kim, K.H.; Floating drug delivery system; An approach to oral controlled drug delivery via gastric retention. J. Control Release, 2000; 63(3): 235- 259.
32. Sreenivas and S. A. Pai, K.V. “Synthesis of thiolated Chitosan: promising polymers for prolong mocoadhesive drug delivery”. Int. J. Pharm-2009; 1(3): 670-678. 5.
33. Tripathi KD (2013) Essentials of Medical Pharmacology, seventh edition, published by Jaypee Brothers Medical Publishers (P) Ltd, 4838/24, Ansari Road, Daryaganj, New Delhi, 110 002, India, first edition 1985, pp 663.
34. Rowe RC, Sheskey PJ, Quinn ME, 2009. Handbook of Pharmaceutical Excipients. 6th edition. Philippines: PhP APhA Pharmaceutical Press. Pages: 298-300, 478- 480,782-784.
35. Rahamathulla M, Srinivasan S, Gangadharappa HV, Development of Valsartan Floating Matrix Tablets Using Low Density Polypropylene Foam Powder: In vitro and In vivo Evaluation, AAPS PharmSciTech 2019; 20(1):20-35.

36. Kenichi Mishima , Yuka Tsukagoshi Okabe , Efficacy of soluble lansoprazole-impregnated beta-tricalcium phosphate for bone regeneration, Sci Rep2022 Nov 29; 12(1):20550. doi: 10.1038/s41598-022-25184-4.
37. Binbin Wei 1, Yan Wang , Pharmacodynamics and Pharmacokinetics of a New Type of Compound Lansoprazole Capsule in Gastric Ulcer Rats Importance of Adjusting Oxidative Stress and Inflammation Pharmaceutics2019; 22;11(2):49.
38. More S, Kaustubh Gavali , Onkar Doke, Prasad Kasgawade, Gastroretentive drug delivery system, Journal of Drug Delivery & Therapeutics. 2018; 8(4):24-35.
39. El Nabarawi MA, Teaima MH, Abd El-Monem RA, El Nabarawy NA, Gaber DA. Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl. Drug Des Devel Ther. 2017; 11:1081–1093.)
40. Kumari SU, B.Ramu2*, G.Srikanth2, Dr.Bigala Rajkamal, Formulation and Evaluation of Sustained Release Lansoprozil Hydrochloride Using Natural Polymers, International Journal of Applied Pharmaceutical Sciences and Research 2016; 1(2):76-87.
41. Dawang SR, Saboo SS, Khadabadi S, Formulation and evaluation of floating tablets of Lansoprozil hydrochloride by using gastroretentive technology, International Journal of Pharmaceutical Sciences Review and Research, 2015, 34(1):263-269.
42. Bharat W. Tekade, Vinod M. Thakare, Umesh T. Jadhao, Fahim Kazi, Optimization and In vitro evaluation of lansoprozil hydrochloride floating bilayer tablet, The Pharma Innovation Journal 2014; 3(6):48-56).
43. Kondeti Ranjith Reddy*, Grace Rathnam, I. Kiran, Shalem Raju and Kranti Sri Mulpuri, Formulation development and evaluation of sustained release matrix tablets of lansoprozil hydrochloride, IJPSR, 2014; 5(5):2066-73.
44. S. Vidyadhara, R. L. C. Sasidhar, V. Uma Maheswara Rao, C. H. Showri Babu, D. Lakshmi Harika, Formulation and evaluation of lansoprozil hydrochloride osmotic controlled release matrix tablets, Asian Journal of Pharmaceutics, 2014; 1(4):102-109.

Published

2023-01-09

How to Cite

Kumar, J., Rajput, D. S., Gupta, N., & Sharma, N. K. (2023). Design, Development and Evaluation of Gastro- Retentive Mucoadhesive Microballons of Lansoprazole for Management of Peptic Ulcer. Asian Journal of Pharmaceutical Research and Development, 10(6), 161–165. https://doi.org/10.22270/ajprd.v10i6.1092

Issue

Vol. 10 No. 6 (2022): Vol 10 No 6 (2022): Volume 10 Issue 6 Nov. - Dec. 2022

Section

Research Articles

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).